Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Ames test:
B508 was tested in the bacterial reverse mutation assay with Salmonella typhimurium TA 1535, TA 1537, TA 100, TA 98 and E. coli WP2uvrA using a pre-incubation method with and without S9-mix. No toxicity was observed up to and including the top dose of 5000 µg/plate. Precipitation was observed at 1250µg/plate and higher.The numbers of revertant colonies in the test substance treatment groups were less than two times compared with that in each negative control in all test strains with and without S9-mix. It is concluded that B508 is not mutagenic under the conditions of this test.
Chromosome aberration test:
A chromosome aberration study with B508 was performed according to OECD 473 guideline and GLP principles, in cultured Chinese hamster lung fibroblasts (CHL/IU cells) with and without S9-mix including a confirmation experiment. Appropriate toxicity was reached at the dose levels selected for scoring. The frequencies of cells with numerical aberrations showed less than 5% at all doses in the short-term treatment with and without S9 -mix and the 24 -hour continuous treatment. The frequencies of cells with structural aberration showed less than 5% at all doses of the test substance in the short-term treatment without S9 and 24 hours continuous treatment without S9. The frequencies of cells with structural aberration was 6.0% at 640 µg/mL in the short-term treatment time with S9 and induction of structural aberration by the test substance was suspected. However, the frequencies of cells with structural aberration showed less than 5% at all doses of the test substance tested in the confirmation experiment under the same conditions. Therefore, it was concluded that B508 is not clastogenic in cultured Chinese hamster lung fibroblasts (CHL/IU cells).
The results of the negative and positive controls were within the historical data range.
Mouse lymphoma assay:
An in vitro mammalian cell gene mutation test with B508 was performed according to OECD 476 guideline and GLP principles, in cultured L5178Y mouse lymphoma cells with and without S9-mix in two independent experiments.
In the first experiment, B508 was tested up to the cytotoxic level of 70% in the absence of S9-mix. No toxicity was observed at the highest dose level tested in the presence of S9-mix. In the second experiment, B508 was tested up to cytotoxic levels of 81 and 30% in the absence and presence of S9-mix, respectively. In the presence of S9 -mix B508 was tested including a precipitating concentration.
In the absence of S9-mix, B508 did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in a repeat experiment with modifications in the duration of treatment time.
In the presence of S9-mix, B508 did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent experiment with modifications in the composition of the S9 concentration for metabolic activation. Positive and negative control data showed valid results.
In conclusion, B508 is not mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described in this report.
Justification for selection of genetic toxicity endpoint
One Ames test, one chromosome aberration test and mouse lymphoma test are available.
Short description of key information:
B508 was tested in the Salmonella typhimurium reverse mutation assay with TA 1535, TA 1537, TA 100, TA 98 and WP2uvrA according to OECD Guideline 471 and GLP principles.
A chromosome aberration study with B508 was performed according to OECD 473 guideline and GLP principles, in cultured Chinese hamster lung fibroblasts (CHL/IU cells) in a chromosomal aberration test and a confirmation experiment.
An in vitro mammalian cell gene mutation test with B508 was performed according to OECD 476 guideline and GLP principles, in cultured L5178Y mouse lymphoma cells.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Based on the available studies, it can be concluded that B508 is not considered mutagenic/clastogenic according to EC regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.